Barker Jerry L, Garden Adam S, Ang K Kian, O'Daniel Jennifer C, Wang He, Court Laurence E, Morrison William H, Rosenthal David I, Chao K S Clifford, Tucker Susan L, Mohan Radhe, Dong Lei
Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):960-70. doi: 10.1016/j.ijrobp.2003.12.024.
Many patients receiving fractionated radiotherapy (RT) for head-and-neck cancer have marked anatomic changes during their course of treatment, including shrinking of the primary tumor or nodal masses, resolving postoperative changes/edema, and changes in overall body habitus/weight loss. We conducted a pilot study to quantify the magnitude of these anatomic changes with systematic CT imaging.
Fourteen assessable patients were enrolled in this pilot study. Eligible patients had to have a pathologic diagnosis of head-and-neck cancer, be treated with definitive external beam RT, and had have gross primary and/or cervical nodal disease measuring at least 4 cm in maximal diameter. All patients were treated using a new commercial integrated CT-linear accelerator system (EXaCT) that allows CT imaging at the daily RT sessions while the patient remains immobilized in the treatment position. CT scans were acquired three times weekly during the entire course of RT, and both gross tumor volumes (GTVs: primary tumor and involved lymph nodes) and normal tissues (parotid glands, spinal canal, mandible, and external contour) were manually contoured on every axial slice. Volumetric and positional changes relative to a central bony reference (the center of mass of the C2 vertebral body) were determined for each structure.
Gross tumor volumes decreased throughout the course of fractionated RT, at a median rate of 0.2 cm(3) per treatment day (range, 0.01-1.95 cm(3)/d). In terms of the percentage of the initial volume, the GTVs decreased at a median rate of 1.8%/treatment day (range, 0.2-3.1%/d). On the last day of treatment, this corresponded to a median total relative loss of 69.5% of the initial GTV (range, 9.9-91.9%). In addition, the center of the mass of shrinking tumors changed position with time, indicating that GTV loss was frequently asymmetric. At treatment completion, the median center of the mass displacement (after corrections for daily setup variation) was 3.3 mm (range, 0-17.3 mm). Parotid glands also decreased in volume (median, 0.19 cm(3)/d range, 0.04-0.84 cm(3)/d), and generally shifted medially (median, 3.1 mm; range, 0-9.9 mm) with time. This medial displacement of the parotid glands correlated highly with the weight loss that occurred during treatment.
Measurable anatomic changes occurred throughout fractionated external beam RT for head-and-neck cancers. These changes in the external contour, shape, and location of the target and critical structures appeared to be significant during the second half of treatment (after 3-4 weeks of treatment) and could have potential dosimetric impact when highly conformal treatment techniques are used. These data may, therefore, be useful in the development of an adaptive RT scheme (periodic adjustment of the conformal treatment plan) that takes into account such treatment-related anatomic changes. In theory, such a strategy would maximize the therapeutic ratio of RT.
许多接受头颈部癌分次放疗(RT)的患者在治疗过程中出现明显的解剖学变化,包括原发肿瘤或淋巴结肿块缩小、术后改变/水肿消退以及全身体型变化/体重减轻。我们进行了一项初步研究,通过系统的CT成像来量化这些解剖学变化的程度。
14名可评估的患者纳入了这项初步研究。符合条件的患者必须有头颈部癌的病理诊断,接受确定性外照射放疗,且原发灶和/或颈部淋巴结疾病最大直径至少为4 cm。所有患者均使用一种新的商用集成CT直线加速器系统(EXaCT)进行治疗,该系统允许在每日放疗期间对患者进行CT成像,同时患者保持在治疗位置固定不动。在整个放疗过程中,每周进行三次CT扫描,在每个轴位切片上手动勾勒出大体肿瘤体积(GTV:原发肿瘤和受累淋巴结)和正常组织(腮腺、椎管、下颌骨和外部轮廓)。确定每个结构相对于中央骨性参考(C2椎体的质心)的体积和位置变化。
在分次放疗过程中,大体肿瘤体积逐渐减小,中位速率为每天0.2 cm³(范围为0.01 - 1.95 cm³/d)。就初始体积的百分比而言,GTV以每天1.8%的中位速率减小(范围为0.2 - 3.1%/d)。在治疗的最后一天,这相当于初始GTV中位总相对损失69.5%(范围为9.9 - 91.9%)。此外,缩小的肿瘤质心随时间发生位置变化,表明GTV的缩小通常是不对称的。治疗结束时,质心位移的中位值(校正每日摆位变化后)为3.3 mm(范围为0 - 17.3 mm)。腮腺体积也减小(中位值为0.19 cm³/d,范围为0.04 - 0.84 cm³/d),并且一般随时间向内移位(中位值为3.1 mm;范围为0 - 9.9 mm)。腮腺的这种向内移位与治疗期间发生的体重减轻高度相关。
在头颈部癌的分次外照射放疗过程中发生了可测量的解剖学变化。这些靶区和关键结构的外部轮廓、形状和位置变化在治疗后半期(治疗3 - 4周后)似乎很显著,并且在使用高度适形治疗技术时可能产生潜在的剂量学影响。因此,这些数据可能有助于制定考虑到此类与治疗相关的解剖学变化的自适应放疗方案(适形治疗计划的定期调整)。理论上,这样的策略将使放疗的治疗比最大化。